Clinical trial
Pergolide for Cognitive Symptoms in Schizotypal Personality Disorder
NCT00252044 · Bronx VA Medical Center, U.S. Fed · Unknown status
Key facts
| NCT number | NCT00252044 |
|---|---|
| Title | Pergolide for Cognitive Symptoms in Schizotypal Personality Disorder |
| Official title | The Dopaminergic System in Schizotypal Personality Disorder: Pergolide for Cognitive Symptoms in Schizotypal Personality Disorder |
| Lead sponsor | Bronx VA Medical Center, U.S. Fed |
| Status | Unknown status |
| Study type | Interventional |
| Conditions | Schizotypal Personality Disorder, Other Personality Disorders |
| Intervention type | Drug |
| Interventions | Pergolide |
| Start date | Oct 1, 2000 |
| First posted | Nov 11, 2005 |
| Last update posted | Nov 21, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: